Format

Send to

Choose Destination
Trends Immunol. 2009 Feb;30(2):83-90. doi: 10.1016/j.it.2008.11.003. Epub 2009 Jan 12.

Complement activation and inhibition: a delicate balance.

Author information

1
University of Copenhagen, Department of Cellular and Molecular Medicine, Faculty of Health Sciences, DK-2200, Copenhagen, Denmark.

Abstract

Complement is part of the innate immune defence and not only recognizes microbes but also unwanted host molecules to enhance phagocytosis and clearance. This process of opsonisation must be tightly regulated to prevent immunopathology. Endogenous ligands such as dying cells, extracellular matrix proteins, pentraxins, amyloid deposits, prions and DNA, all bind the complement activator C1q, but also interact with complement inhibitors C4b-binding protein and factor H. This contrasts to the interaction between C1q and immune complexes, in which case no inhibitors bind, resulting in full complement activation. Disturbances to the complement regulation on endogenous ligands can lead to diseases such as age-related macular degeneration, neurological and rheumatic disorders. A thorough understanding of these processes might be crucial to developing new therapeutic strategies.

PMID:
19144569
DOI:
10.1016/j.it.2008.11.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center